Analysts think EDSA stock price could increase by 356%
Jun 14, 2024, 6:28 AM
-9.80%
What does EDSA do
Edesa Biotech Inc, based in Markham, Ontario, is a clinical-stage biopharmaceutical company focusing on inflammatory and immune-related diseases with key drug candidates in various trial phases, including a Phase III study for ARDS. The company, which went public in 2008, is developing treatments like EB05 for ARDS and EB01 for chronic allergic contact dermatitis, along with other products for chronic dermatological conditions.
4 analysts think EDSA stock price will increase by 355.56%. The current median analyst target is $20.91 compared to a current stock price of $4.59. The lowest analysts target is $20.20 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
